Avis Budget Group Inc (CAR) Stock News

Paccar (PCAR) closed down 1.48% to $108.04, underperforming the S&P 500's 0.6% gain. The truck maker has lost 10.53% over the past month but maintains a Zacks Rank #2 (Buy) rating. Analysts expect strong Q3 earnings of $1.61 EPS (up 43.75% YoY) and full-year revenue of $28.61 billion (up 9.05% YoY), though the stock trades at a premium valuation with a Forward P/E of 18.57 versus the industry average of 16.06.

Paccar (PCAR) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The truck maker is expected to earn $5.91 per share for fiscal year 2026, with analysts raising consensus estimates by 5.8% over the past three months. The upgrade positions Paccar in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation.

The Canine Project, a dog beauty and skincare brand, announced the October 15 launch of FURVIVE™ Restorative Shampoo + Conditioner + Body Wash. The all-in-one product combines Brazilian Copaiba botanical with premium skincare ingredients like Niacinamide, Hyaluronic Acid, and Argan Oil, formulated specifically for canine skin. Priced at $33 for 12 fl oz, it will be available on the company's website and Amazon.

Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant across 12 key markets, expanding its Sports Medicine portfolio. The product is backed by clinical evidence showing superior knee outcomes and pain relief over five years. The global cartilage repair market is projected to grow from $5.98 billion in 2024 to $8.04 billion by 2030 at a 5.1% CAGR.

Paccar (PCAR) closed down 2.25% and has declined 10.76% over the past month, underperforming the S&P 500. The truck maker is expected to report strong earnings growth of 43.75% EPS increase and 23.48% revenue growth for the upcoming quarter. However, the stock carries a Zacks Rank #3 (Hold) rating with a Forward P/E of 18.51, trading at a premium to its industry average of 16.41.

Smith+Nephew announced the commercial availability of its CARTIHEAL AGILI-C cartilage repair implant in Europe, following its 2024 US launch. The aragonite-based implant demonstrated clinical superiority over standard care in a multicenter randomized controlled trial, showing superior pain relief and functional gains over 5 years. The product will initially be available in 12 European countries.

Smith+Nephew announced the commercial launch of CARTIHEAL AGILI-C, an innovative cartilage repair implant, across Europe. The aragonite-based scaffold will be presented at the ICRS Summit in Portugal (October 8-10). A randomized controlled trial published in the American Journal of Sports Medicine demonstrated clinical superiority over standard surgical care, with patients showing improved pain relief and functional outcomes over 5 years. The implant will initially be available in 8 European countries with plans for further expansion.

Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.

Paccar stock fell 1.65% to $109.96, underperforming the S&P 500's 0.25% loss. The truck maker has declined 8.7% over the past month. However, the company is expected to report strong earnings growth of 43.75% EPS increase and 23.48% revenue growth year-over-year, with a Zacks Rank #2 (Buy) rating. The stock trades at a premium valuation with a Forward P/E of 18.93 versus the industry average of 15.79.

ECARX Holdings, Inc. (ECX) has been upgraded to a Zacks Rank #2 (Buy) rating due to rising earnings estimates. The company's consensus estimate for fiscal year 2026 remains at -$0.02 per share, but analysts have increased their estimates by 50% over the past three months. The upgrade positions ECX in the top 20% of Zacks-covered stocks, suggesting potential near-term stock price appreciation.

A securities class action lawsuit has been filed against Avis Budget Group, Inc. and Pentwater Capital Management LP, alleging that defendants orchestrated a market manipulation scheme. Pentwater, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during the Class Period (February 20, 2025 - April 21, 2026) that triggered unusual volatility and a short squeeze, artificially inflating Avis stock prices to benefit Pentwater's holdings. Investors who purchased Avis securities during this period may be eligible for compensation. The lead plaintiff deadline is September 29, 2026.

Kaplan Fox has filed securities class action lawsuits against Avis Budget Group, Alibaba Group, and Pentair plc on behalf of investors who suffered losses. The primary case against Avis alleges a market manipulation scheme orchestrated by Pentwater Capital Management, which held approximately 51% economic interest in the company and allegedly triggered unusual volatility through aggressive stock purchases during the class period.

Pomerantz Law Firm has filed a class action lawsuit on behalf of Avis Budget Group investors, alleging that Pentwater Capital Management and CEO Matthew Halbower orchestrated a market manipulation scheme. Pentwater, holding approximately 51% of Avis through stocks and swaps, allegedly triggered a short squeeze that drove Avis stock from $147.52 to $765.94 (419% increase) in April 2026, only to collapse 74.51% after Pentwater sold 4.3 million shares. Pentwater agreed to pay Avis $650 million to settle alleged short-swing profits violations.

Rosen Law Firm announces securities class action lawsuits against Avis Budget Group, AppLovin Corporation, and Bloom Energy Corporation. The Avis lawsuit alleges that Pentwater Capital Management LP and its CEO orchestrated a market manipulation scheme involving aggressive stock purchases that triggered a short squeeze, artificially inflating stock prices. Investors with losses exceeding $100,000 are encouraged to join the class actions before upcoming deadlines.

Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will showcase clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration capabilities, as well as updates on the Phase 1/2 COMPLETE Trial for FT839, a dual-CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases.

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

The CAR-T cell therapy market for acute lymphoblastic leukemia (ALL) is projected to grow at a 6.8% CAGR from 2026 to 2036, reaching from $300 million in 2025. The market is driven by approved therapies like KYMRIAH, TECARTUS, and AUCATZYL, with emerging innovations including allogeneic platforms and CD7-targeting therapies. Key challenges include relapse rates, manufacturing complexity, and toxicity management, while opportunities exist in earlier treatment lines and off-the-shelf platforms.

HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.

ResearchAndMarkets.com released a comprehensive analytical tool tracking CAR/TCR/TIL therapies in oncology, monitoring 870+ organizations and 2,370+ drugs across the pipeline. The tool provides competitive intelligence on leading developers including Gilead Sciences, Cellectis, MediGene, GenScript, and CARsgen Therapeutics, with 236 new therapies added in 2024/25 and over 1,700 BD&L contacts for partnership opportunities.

Rosen Law Firm is notifying investors in Avis Budget Group (CAR) and Park Ha Biological Technology (PHH, BYAH) about ongoing securities class action lawsuits. The Avis lawsuit alleges that Pentwater Capital Management LP and its CEO orchestrated a market manipulation scheme involving aggressive stock purchases that triggered a short squeeze, artificially inflating stock prices. Investors with losses exceeding $100,000 are encouraged to join the class action before the September 29, 2026 deadline.

Comstock Resources (CRK) has announced a $1.65 billion strategic partnership with Azerbaijan's SOCAR and a $450 million drilling joint venture with Jerry Jones. The deals will reduce pro forma net debt from $3.1 billion to $1.5 billion, provide LNG marketing capabilities, and fund drilling of 27 wells in the Haynesville while CRK retains operational control. The SOCAR transaction is expected to close by year-end 2026.

Broad Arrow Auctions, driven by Hagerty, is hosting its second annual Zürich Auction on November 7, 2026, at the Dolder Grand. The sale will feature approximately 60 collector cars, headlined by a rare 2019 McLaren Senna (est. CHF 1.1-1.4M) and a 2015 Ferrari LaFerrari offered without reserve (est. CHF 5.5-7.5M), alongside a 2011 Lamborghini Gallardo LP570-4 Superleggera. The auction continues Broad Arrow's partnership with Auto Zürich.

Avis Budget Group faces a securities class action lawsuit alleging that defendants Pentwater and Halbower manipulated the market for Avis securities through aggressive stock purchases that triggered a short squeeze. The stock surged 419% to $765.94 on April 21, 2026, before collapsing 74.51% to $182.01 by April 28. Investors with losses exceeding $100,000 have until September 29, 2026 to file lead plaintiff applications.

Rosen Law Firm is notifying investors in Avis Budget Group, ARS Pharmaceuticals, and Bloom Energy Corporation of ongoing securities class action lawsuits. The primary case involves allegations that Pentwater Capital Management LP and its CEO manipulated Avis stock prices through aggressive purchasing that triggered a short squeeze, benefiting Pentwater's substantial holdings. Investors with losses exceeding $100K are encouraged to join the class actions before the September 29, 2026 deadline.

A class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they accumulated a massive stake in Avis Budget Group while artificially driving up the stock price through a short-squeeze dynamic. The complaint claims that after the stock peaked at $847.70 per share on April 21, 2026, Pentwater sold 4.3 million shares over two days for $1.75 billion, causing the share price to plummet. Investors who purchased Avis securities between February 20 and April 21, 2026 can seek appointment as lead plaintiff by September 29, 2026.

The Zacks Domestic Auto industry is showing resilience with new-vehicle sales remaining healthy, supported primarily by affluent consumers. The EV market shows mixed signals with modest adoption rates, while potential tax refunds and auto-loan interest deductions could provide near-term demand support. Four major automakers—General Motors, PACCAR, Ford, and Harley-Davidson—are positioned to benefit from industry tailwinds and are recommended for investor consideration.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.

Rosen Law Firm has filed a class action lawsuit against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group securities. The defendants allegedly used their position as a major shareholder (holding ~51% economic interest) to aggressively purchase Avis stock during February 2025 to April 2026, triggering a short squeeze and artificial price volatility that benefited their holdings. Investors who purchased Avis securities during this period may be eligible for compensation.

Bernstein Liebhard LLP has filed securities class action lawsuits against Avis Budget Group for allegedly orchestrating a market manipulation scheme involving short squeezes, and is investigating potential breaches of fiduciary duty at Capricor Therapeutics and Calix. Investors who suffered losses during the specified periods are encouraged to participate in the class actions.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.